Abstract:BACKGROUND: Vascular endothelial growth factor (VEGF) can specifically promote the division and proliferation of endothelial cells and the revascularization, finally induce angiopoiesis. Recently, VEGF-based gene therapy has been gradually used in clinical trials, but some limits on usually used vectors deserve further studies, including the low transfection efficiency of plasmid vector, the immunogenicity of adnovirus vector to host cells and the potential risk of infection. OBJECTIVE: To construct the non-pathogenic recombinant adeno-associated vires (AAV) co-expressing human vascular endethelial growth factor 165 (hVEGF165) and green fluorescent protein (GFP) label and measure the virus titer and assess its biological activity.DESIGN, TIME AND SETTING: The open experiment was performed at the Vitrus Laboratory of Shanxi Provincial Center for Disease Control and Prevention from March to September 2007.MATERIALS: AAV-293 virus packaging cell line, AAV HT-1080 cells were purchased from Swatagene, USA. E.coli DH5α was a stocked strain from Shanxi Provincial Center for Disease Control and Prevention. AAV Helper Free System (pAAV-IRES-GFP vector containing GFP label) was purchased from Stratagene, USA. Plasmid pUC18-hVEGF165 was constructed previously by Dr.Shi from Department of Orthopaedics of Second Affiliated Hospital of Xi'an Jiaotong University.METHODS: The hVEGF165 gone from plasmid pUC18-hVEGF165 was amplified and inserted into plasmid pAAV-IRES-hrGFP. Then recombinant plasmid pAAV-hVEGF165-IRES-hrGFP, pAAV-RC and pAAV-Helper were co-transfected into AAV-293 cells to complete rAAV-hVEGF165-IRES-hrGFP packaging through homologous recombination. The efficiency of A.AV packaging was monitored under a fluorescent microscope, and the recombinant viral particles were harvested from infected AAV-293 cells and further concentrated and purified. The recombinant virus infected the AAV-HT1080 cells, the virus titer was measured by fluorescence counting, and the recombinant AAV-hVEGF165-IRES-hrGFP was verified by the amplification of the exogenous gene of hVEGF165 from virus genome.MAIN OUTCOME MEASURES: Virus packaging efficiency was monitored under the fluorescence microscope. Virus filer was measured by fluorescent counting. The packaging of recombinant virus was determined by the amplification of the exogenous hVEGF165 gene.RESULTS: The amplified products were verified as hVEGF165 gene by DNA sequencing, and the recombinant pAAV-hVEGF165-IRES-hrGFP was confirmed by double digestion. The system provided a high packaging ratio of over 95% and the purified recombinant virus had a high titer of 5.5×1011 vp/mL. The recombinant virus was confirmed by exogenous human VEGF165 gene from virus genome.CONCLUSION: The non-pathogenic rAAV-hVEGF165-GFP simultaneously carrying hVEGF165 and GFP 1abel is successfully constructed, with a high titer and satisfying biological activity.

Construction of Recombinant Adenoviruse Vector Containing Tissue-Type Plasminogen Activator and Its Effect on the Expression of VEGF in the Transfected Active ECV304 Cells

Expression of vascular endothelial growth factor in ECV304 cells up-regulated by exogenous tissue-type plasminogen activator via extracellular regulated protein kinases signaling pathway

Study on Inhibitation of the Tube Formation by RNA Introduced by Adenovirus by its Interference With and Decrease of VEGF Transcription

Construction and Target Gene Expression of Recombinant Adenovirus Vectors Containing Vascular Endothelial Growth Factor 165 and Angiopoietin-1

Construction and Identification of Recombinant Adeno- Associated Virus Vector Co-Expressing Human Vascular Endothelial Growth Factor and Green Fluorescent Protein

Construction and target gene expression of adenovirus vectors containing angiogenin-1/vascular endothelial growth factor 165

Construction of Recombinant Adenoviral Vector Co-Expressing Vascular Cell Adhesion Molecules-1 and Enhanced Green Fluorescent Protein

The expression of tPA gene transduced into endothelium of ECV304

Construction of Recombinant Adenovirus Coding for Vascular Endothelial Growth Factor Gene

Construction of Recombinant Adenoviruse Vector Containing Human Vascular Endothelial Growth Factor and Its Expression in Mesenchymal Stem Cells

A study on biological activity of co-expression plasmid of human tissue plasminogen activator and vascular endothelial growth factor 165

Construction of Eukaryotic Expression Plasmid Containing Tpa Genes and Its Expression in Transfected VSMCs

Promotive effect of polytetrafluoroethylene vascular grafts carrying VEGF gene on the growth of endothelial cells

Construction and Expression of Bicistronic Adenovirus Vector Carrying Thymidine Kinase and Enhanced Green Fluorescent Protein Gene.

[Effects of Co-Expression Plasmid of Human Tpa and VEGF165 on the Proliferation of Vascular Cells and Fibrinolysis Activity].

Local Epression and Thrombolysis of Retroviral Vector with Tissue Type Plasminogen Activator Gene

[Construction of Co-Expression Plasmid Containing Tpa and VEGF165 Genes and Its Expression in VSMCs].

Construction of tetracycline-regulative adenoviral vector containing human vascular endothelial growth factor 165 gene and its expression in rat myoblast

Construction of hVEGF165 Recombinant Adenovirus Vector and Its Expression in HEK293 Cells

In vivo expression of human tissue-plasminogen activator transfected AGZY83-a cells implanted in mice

Expression of vascular endothelial growth factor in endothelial progenitor cells following its expression vector construction